


Stabilis



Cefoxitin sodium



Tradename

Cefoxitin	Australia, Austria, Canada, United States of America
Cefoxitina	Argentina, Brazil, Colombia, Portugal, Spain
Cefton	Brazil
Destrepen	Greece
Foxitin	Portugal, Saudi Arabia, United Arab Emirates
Kefox	Brazil, Greece
Mefoxil	Greece
Mefoxin	Italy, Netherlands, United States of America
Mefoxitin	Austria, Venezuela
Metaptyl	Greece
Renoxitin	Great Britain



Stability in solutions

		20 mg/ml	25°C		48			418
PVC		40 mg/ml	-20°C		30			440
PVC		20 mg/ml	-20°C		30			576
		125 mg/ml	20-25°C		12			4634
PI		5 & 60 mg/ml	4°C		10			604



Stability of mixtures

		20 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48		418
		5 mg/ml	25°C		Magnesium sulfate : 10 & 20 mg/ml	20		630
		30 mg/ml	25°C		Metronidazole : 5 mg/ml	2		631
		30 mg/ml	25°C		Metronidazole : 5 mg/ml	2		631

		30 mg/ml	5°C		Metronidazole : 5 mg/ml	12		631
PVC		10 & 20 mg/ml	25°C		Aztreonam : 10 & 20 mg/ml	12		19
PVC		10 & 20 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		19



Compatibility

		Cefoxitin sodium : 0,3 mg/ml		4693
		Cefoxitin sodium Amikacin sulfate		3549
		Cefoxitin sodium : 20 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Cefoxitin sodium : 20 mg/ml		301
		Cefoxitin sodium : 200 mg/ml		939
		Cefoxitin sodium : 95 mg/ml		999
		Cefoxitin sodium : 20 mg/ml		1415
		Cefoxitin sodium : 100 mg/ml	RL	4603
		Cefoxitin sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		336
		Cefoxitin sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Cefoxitin sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Cefoxitin sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Cefoxitin sodium : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Cefoxitin sodium : 20 mg/ml Aztreonam : 40 mg/ml		99
		Cefoxitin sodium : 10 & 20 mg/ml Aztreonam : 10 & 20 mg/ml		19
		Cefoxitin sodium : 20 mg/ml Bivalirudin : 5 mg/ml		1713
		Cefoxitin sodium : 100 mg/ml Caffeine : 10 mg/ml		3964
		Cefoxitin sodium : 10 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Cefoxitin sodium : 20 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Cefoxitin sodium : 20 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
		Cefoxitin sodium : 20 mg/ml Clindamycin phosphate : 9 mg/ml		418
		Cefoxitin sodium Clindamycin phosphate		3526

		Cefoxitin sodium : 100 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Cefoxitin sodium : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Cefoxitin sodium : 200 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Cefoxitin sodium : 10 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Cefoxitin sodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefoxitin sodium : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Cefoxitin sodium Erythromycin lactobionate		3674
		Cefoxitin sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cefoxitin sodium : 20 mg/ml Famotidine		397
		Cefoxitin sodium : 20 mg/ml Famotidine : 2 mg/ml		215
		Cefoxitin sodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Cefoxitin sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Cefoxitin sodium : 40 mg/ml Fluconazole : 2 mg/ml		496
		Cefoxitin sodium : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
		Cefoxitin sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cefoxitin sodium Gentamicin sulfate		3643
		Cefoxitin sodium Gentamicin sulfate		3520
		Cefoxitin sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefoxitin sodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefoxitin sodium : 20 mg/ml Hetastarch : 60 mg/ml		472
		Cefoxitin sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefoxitin sodium : 100 mg/ml Imipenem - cilastatin sodium : 50 mg/ml		4389
		Cefoxitin sodium : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cefoxitin sodium : 20 mg/ml Linezolid : 2 mg/ml		1925
		Cefoxitin sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Cefoxitin sodium : 5 mg/ml Magnesium sulfate : 10 & 20 mg/ml		630

		Cefoxitin sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Cefoxitin sodium : 30 mg/ml Metronidazole : 5 mg/ml		1035
		Cefoxitin sodium Metronidazole		3594
		Cefoxitin sodium : 30 mg/ml Metronidazole : 5 mg/ml		631
		Cefoxitin sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
		Cefoxitin sodium : 40 mg/ml Morphine sulfate : 1 mg/ml		406
		Cefoxitin sodium N-acetylcysteine : 200 mg/ml		3766
		Cefoxitin sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Cefoxitin sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cefoxitin sodium Pantoprazole sodium		2090
		Cefoxitin sodium : 100 mg/ml Paracetamol : 10 mg/ml		3571
		Cefoxitin sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefoxitin sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cefoxitin sodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
		Cefoxitin sodium : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Cefoxitin sodium : 40 mg/ml Pethidine hydrochloride : 10 mg/ml		406
		Cefoxitin sodium : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Cefoxitin sodium : 20 mg/ml Propofol : 10 mg/ml		300
		Cefoxitin sodium : 20 mg/ml Ranitidine hydrochloride : 1 mg/ml		2355
		Cefoxitin sodium : 20 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Cefoxitin sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Cefoxitin sodium : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Cefoxitin sodium : 20 mg/ml Teniposide : 0.1 mg/ml		905
		Cefoxitin sodium : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
		Cefoxitin sodium : 20 mg/ml Thiotepa : 1 mg/ml		249
		Cefoxitin sodium : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674

		Cefoxitin sodium : 10 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Cefoxitin sodium : 1 >> 180 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
		Cefoxitin sodium : 50 & 180 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Cefoxitin sodium : 4 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057



Route of administration



References

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
19	Journal	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Journal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Journal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Journal	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
275	Journal	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
336	Journal	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
397	Journal	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
405	Journal	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Journal	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
418	Journal	Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, ceftoxime sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm 1985 ; 42: 2211-2214.
440	Journal	Stiles ML, Tu YH, Allen LV. Stability of cefazolin sodium, ceftoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm 1989 ; 46: 1408-1412.
472	Journal	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
576	Journal	Holmes CJ, Ausman RK, Walter CW, Kundsinn RB. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm 1980 ; 14: 353-357.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
630	Journal	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.





















































631	Journal	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Journal	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
999	Journal	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Journal	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Journal	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Journal	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1201	Journal	Yuhás EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1674	Journal	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.

1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2355	Journal	Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M. Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration. Int J Pharm Compound 2000 ; 4, 2: 150-153.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Manufacturer	Cidomycin - Summary of product Characteristics. Sanofi 2011
3526	Manufacturer	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Manufacturer	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	Journal	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3594	Manufacturer	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Manufacturer	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.

3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Journal	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévamisolan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	Journal	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4693	Journal	Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. Drug Design Dev Ther 2022 ;16:1433-1440.
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionary

 Antibiotic	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 NaCl 0,9% or Glucose 5%	 Light
 Hour	 Polyvinyl chloride
 Water for Injection	 Protect from light
 Day	 Glucose 5%
 Polypropylen Syringe	 Polyisoprene elastomer
 Stability of mixtures	 Solvent
 Compound	 None
 Not specified	 Compatibility
 Compatible	 NaCl 0.225 % + glucose 3.75%
 Chemical instability	 Incompatible
 Parenteral nutrition (binary mixture)	 Parenteral nutrition (with lipids)
RL Ringer's lactate solution	 Immediate turbidity
 Sodium chloride 0,9%	 Unspecified incompatibility
 Immediate precipitation	 specific solvent
 Precipitation after 1 hour	 Precipitation after 4 hours
 Color change	 Turbidity in 4 hours
 Route of administration	 Intravenous
 Intravenous infusion	 Continuous infusion
 Intramuscular	 References
 Dictionary	